Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection
Uloženo v:
| Název: | Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection |
|---|---|
| Autoři: | Sheba Ziyenge, Pat Tsang, David Bonsall, Manu Shankar-Hari, Peter Simmonds, Tanya Golubchik, Aislinn Jennings, Rutger J. Ploeg, Ullrich Leuscher, Sarah Williams, Matthew Fish, Jennifer Rynne, Wendy Slack, Nick A Ciccone, Amy Evans, David K. Menon, Lise J Estcourt, Marta S Oliveira, Abigail Lamikanra, Farah Al-Beidh, Heli Harvala, Jeremy Ratcliff, David J. Roberts, Dung Nguyen, Kathryn M Rowan, Emma Laing, Paul R Mouncey, Anthony C. Gordon |
| Přispěvatelé: | NIHR, National Institute for Health Research |
| Zdroj: | J Infect Dis 2021, ' Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom : Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection ', The Journal of Infectious Diseases, vol. 224, no. 4, pp. 595-605 . https://doi.org/10.1093/infdis/jiab283 |
| Informace o vydavateli: | Oxford University Press (OUP), 2021. |
| Rok vydání: | 2021 |
| Témata: | Male, 0301 basic medicine, polymerase chain reaction, coronavirus, Passive, Antibodies, Viral, Polymerase Chain Reaction, Viral, Antibodies, Viral/immunology, clade B.1.1.7, Neutralizing, Immunoglobulin G/immunology, 11 Medical and Health Sciences, 0303 health sciences, Middle Aged, Viral Load, Antibodies, Neutralizing/immunology, Spike Glycoprotein, viral load, 3. Good health, COVID-19/immunology, convalescent plasma, Spike Glycoprotein, Coronavirus, RNA, Viral, ELISA, Female, variant of concern, Critical Illness, Microbiology, Antibodies, SARS-CoV-2/immunology, Major Articles and Brief Reports, 03 medical and health sciences, Humans, Serologic Tests, COVID-19 Serotherapy, Aged, Serologic Tests/methods, SARS-CoV-2, Viral Load/immunology, SARS-CoV-2 COVID-19, Immunization, Passive, COVID-19, RNA, Viral/immunology, 06 Biological Sciences, randomized clinical trial, Antibodies, Neutralizing, United Kingdom, REMAP-CAP Immunoglobulin Domain UK Investigators, Coronavirus, Immunoglobulin G, RNA, Immunization, Spike Glycoprotein, Coronavirus/immunology |
| Popis: | BackgroundConvalescent plasma containing neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is under investigation for coronavirus disease 2019 (COVID-19) treatment. We report diverse virological characteristics of UK intensive care patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomized controlled trial that potentially influence treatment outcomes.MethodsSARS-CoV-2 RNA in nasopharyngeal swabs collected pretreatment was quantified by PCR. Antibody status was determined by spike-protein ELISA. B.1.1.7 was differentiated from other SARS-CoV-2 strains using allele-specific probes or restriction site polymorphism (SfcI) targeting D1118H.ResultsOf 1274 subjects, 90% were PCR positive with viral loads 118–1.7 × 1011IU/mL. Median viral loads were 40-fold higher in those IgG seronegative (n = 354; 28%) compared to seropositives (n = 939; 72%). Frequencies of B.1.1.7 increased from ConclusionsHigh viral loads in seropositive B.1.1.7-infected subjects and resistance to seroconversion indicate less effective clearance by innate and adaptive immune responses. SARS-CoV-2 strain, viral loads, and antibody status define subgroups for analysis of treatment efficacy. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/jiab283 |
| Přístupová URL adresa: | https://academic.oup.com/jid/article-pdf/224/4/595/39761243/jiab283.pdf https://pubmed.ncbi.nlm.nih.gov/34031695 https://www.ncbi.nlm.nih.gov/pubmed/34031695 https://academic.oup.com/jid/article/224/4/595/6283590 https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1367024 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241475 https://ora.ox.ac.uk/objects/uuid:98b5fd00-9aa0-46a4-b01c-082a88cf836e https://pubmed.ncbi.nlm.nih.gov/34031695/ http://hdl.handle.net/10044/1/89200 https://www.pure.ed.ac.uk/ws/files/258828893/jiab283.pdf https://hdl.handle.net/20.500.11820/ccd272cc-f618-45a8-9649-3a16e8fe3d4f |
| Rights: | CC BY NC ND URL: http://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (http://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| Přístupové číslo: | edsair.doi.dedup.....3935a99113299cb16abdecddfb35876e |
| Databáze: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstrakt: | BackgroundConvalescent plasma containing neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is under investigation for coronavirus disease 2019 (COVID-19) treatment. We report diverse virological characteristics of UK intensive care patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomized controlled trial that potentially influence treatment outcomes.MethodsSARS-CoV-2 RNA in nasopharyngeal swabs collected pretreatment was quantified by PCR. Antibody status was determined by spike-protein ELISA. B.1.1.7 was differentiated from other SARS-CoV-2 strains using allele-specific probes or restriction site polymorphism (SfcI) targeting D1118H.ResultsOf 1274 subjects, 90% were PCR positive with viral loads 118–1.7 × 1011IU/mL. Median viral loads were 40-fold higher in those IgG seronegative (n = 354; 28%) compared to seropositives (n = 939; 72%). Frequencies of B.1.1.7 increased from ConclusionsHigh viral loads in seropositive B.1.1.7-infected subjects and resistance to seroconversion indicate less effective clearance by innate and adaptive immune responses. SARS-CoV-2 strain, viral loads, and antibody status define subgroups for analysis of treatment efficacy. |
|---|---|
| ISSN: | 15376613 00221899 |
| DOI: | 10.1093/infdis/jiab283 |